Open Orphan PLC (AIM:ORPH, OTC:OPORF) has appointed a chief executive.
He is Yamin 'Mo' Khan, who currently serves as an independent director of the contract research specialist.
Executive chairman Cathal Friel will continue in his role.
Khan brings with him 25 years of experience in contract research, 19 of them with Pharm-Olam International, where he held business development and management roles.
“In the few short months since he joined us, Mo has shared with us his invaluable experience and knowledge of the CRO industry to the benefit of the company,” said Friel.
“With substantial growth across the global infectious and respiratory disease market, the company has experienced a significant increase in human challenge study contract negotiations.
"The appointment of Mo as CEO adds considerable CRO experience and expertise to our contract negotiations and will allow me to focus my attention on other areas of the business to deliver shareholder value and it is my intention to remain very hands on and involved in the business as we go forward.”